ProfileGDS5678 / 1416222_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 83% 80% 81% 83% 83% 84% 83% 82% 87% 83% 80% 82% 83% 84% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.9959183
GSM967853U87-EV human glioblastoma xenograft - Control 25.6691180
GSM967854U87-EV human glioblastoma xenograft - Control 35.839481
GSM967855U87-EV human glioblastoma xenograft - Control 46.2918783
GSM967856U87-EV human glioblastoma xenograft - Control 56.0793883
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.9736984
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.8816883
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.9576882
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.5912487
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.0543983
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.7090880
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.9964582
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.0845883
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.1749984